Amber Therapeutics

Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. With the acquisition of Finetech Medical Limited and Bioinduction Ltd in 2023, we are continuing to be the only UK based company in the field of designing and manufacturing long-term implantables. We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation. Amber UI is the company’s first therapy, aiming to restore normal physiological function in women suffering with mixed urinary incontinence.